Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Puma Biotechnology Inc.

www.pumabiotechnology.com

Latest From Puma Biotechnology Inc.

SOPHIA Positions MacroGenics' Margetuximab For Role In HER2-Positive Breast Cancer

MacroGenics' BLA for full approval in the US is under way and the company already has established a manufacturing facility in preparation for a launch.

Clinical Trials Research and Development Strategies

Puma Beats Most Of Stock Drop Suit Over Nerlynx Study Statements

Jury finds one comment in an investor call was false or misleading, limits damages award to $4.50 per share, or $64,000 for the lead plaintiff, a fraction of what was sought. Case suggests that sometimes taking a stock drop case to trial may limit liability.

Legal Issues BioPharmaceutical

Deal Watch: Celgene Makes Alliances With Kyn, Obsidian After Bristol Buyout

Just two weeks after agreeing on a merger with Bristol, Celgene is back at its own deal-making, signing cancer-focused R&D pacts with Kyn and Obsidian. Boehringer and Bioharmony collaborate on novel therapies for hospital-acquired infections, while Sanofi teams with Biomunex on bi- and multi-specific antibodies.

Business Strategies Commercial

Rare But Real: How One Startup Is Willing Itself To Lift China Orphan Drug Market

As a promising market for orphan drugs, China has seen several approvals in this space in the past six months, mostly from multinationals. But Beijing-based CANbridge believes that a smaller biotech also has a good shot at a leadership role, despite a lack of funding and reimbursement and prickly pricing issues.

China Rare Diseases
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Puma Biotechnology Inc.
  • Senior Management
  • Alan H Auerbach, Pres. & CEO
    Richard Bryce, CMO & CSO
    Maximo F Nougues, CHO
    Steven Lo, Chief Commercial Officer
  • Contact Info
  • Puma Biotechnology Inc.
    Phone: (424) 248-6500
    10880 Wilshire Blvd.
    Ste. 2150
    Los Angeles, CA 90024
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register